[영국] 경쟁시장청, 2개 제약회사에 £2억6000만파운드 벌금 부과
2021-07-20
영국 규제기관인 경쟁시장청(CMA)에 따르면 국내 2개의 제약회사에 £2억6000만파운드 이상의 벌금을 부과했다.
오든 맥켄지(Auden Mckenzie)와 액타비스 UK(Actavis UK)는 국가 공공의료서비스인 국민보건서비스(NHS)에 하이드로코티손 알약 가격을 거의 10년 동안 부풀려 부과한 것으로 드러났다.
2008년 4월 판매된 하이드로코티손 10mg 알약 1팩 가격은 P70펜스였다. 2016년 3월 판매된 가격은 £88파운드로 조사됐다. 8년 동안 1만% 이상 가격이 인상된 것이다.
오든 맥켄지와 액타비스 UK는 하이드로코티손 알약 가격을 부풀리기 위해 공급업체로서의 위치를 남용한 것으로 조사됐다. 또한 다른 경쟁업체가 하이드로코티손 알약을 시장에 출시하지 못하도록 뇌물을 준 것도 드러났다.
국내 수만 명의 사람들은 애디슨병과 같은 생명을 위협하는 질환들을 포함한 부신부전증을 치료하기 위해 하이드로코티손 알약에 의존하고 있다.
▲경쟁시장청(CMA) 홈페이지
----------------------
UK drug companies fined £260m for inflating prices for NHS
Watchdog issues warning after abuses that included paying would-be rivals to stay out of the market
15 july 2021
The UK’s competition watchdog has imposed fines totalling more than £260m on pharmaceutical companies after an investigation found that they overcharged the NHS for hydrocortisone tablets for almost a decade.
The Competition and Markets Authority (CMA) found that the drug’s makers Auden Mckenzie and Actavis UK, now known as Accord-UK, used their position as the sole providers of hydrocortisone to inflate the price of the drug . Tens of thousands of people in the UK depend on hydrocortisone tablets to treat adrenal insufficiency, which includes life-threatening conditions such as Addison’s disease, the CMA said.
The investigation found that the companies were able to inflate the price of hydrocortisone tablets by more than 10,000% compared with the original branded version on sale in 2008. This meant the amount the NHS had to pay for a single pack of 10mg tablets rose from 70p in April 2008 to £88 by March 2016.
The companies also paid would-be rivals to stay out of the market, the watchdog found.
“These are without doubt some of the most serious abuses we have uncovered in recent years,” said Andrea Coscelli, the chief executive of the CMA. “The actions of these firms cost the NHS – and therefore taxpayers – hundreds of millions of pounds.”
Before April 2008, the NHS spent about £500,000 a year on hydrocortisone tablets but this had risen to more than £80m by 2016.
The decision to increase the price of de-branded drugs meant that the NHS “had no choice but to pay huge sums of taxpayers’ money for life-saving medicines” and reduce the money available for patient care , Coscelli said.
“Our fine serves as a warning to any other drug firm planning to exploit the NHS.”
Accord-UK plans to appeal against the CMA’s decision. A spokesman said the company was “very disappointed” by the fine, which relates to activity before the company acquired Actavis in 2017. It said it has “done nothing but continuously reduce the price in the face of significant competition” since the acquisition.
“We maintain that the case a
오든 맥켄지(Auden Mckenzie)와 액타비스 UK(Actavis UK)는 국가 공공의료서비스인 국민보건서비스(NHS)에 하이드로코티손 알약 가격을 거의 10년 동안 부풀려 부과한 것으로 드러났다.
2008년 4월 판매된 하이드로코티손 10mg 알약 1팩 가격은 P70펜스였다. 2016년 3월 판매된 가격은 £88파운드로 조사됐다. 8년 동안 1만% 이상 가격이 인상된 것이다.
오든 맥켄지와 액타비스 UK는 하이드로코티손 알약 가격을 부풀리기 위해 공급업체로서의 위치를 남용한 것으로 조사됐다. 또한 다른 경쟁업체가 하이드로코티손 알약을 시장에 출시하지 못하도록 뇌물을 준 것도 드러났다.
국내 수만 명의 사람들은 애디슨병과 같은 생명을 위협하는 질환들을 포함한 부신부전증을 치료하기 위해 하이드로코티손 알약에 의존하고 있다.
▲경쟁시장청(CMA) 홈페이지
----------------------
UK drug companies fined £260m for inflating prices for NHS
Watchdog issues warning after abuses that included paying would-be rivals to stay out of the market
15 july 2021
The UK’s competition watchdog has imposed fines totalling more than £260m on pharmaceutical companies after an investigation found that they overcharged the NHS for hydrocortisone tablets for almost a decade.
The Competition and Markets Authority (CMA) found that the drug’s makers Auden Mckenzie and Actavis UK, now known as Accord-UK, used their position as the sole providers of hydrocortisone to inflate the price of the drug . Tens of thousands of people in the UK depend on hydrocortisone tablets to treat adrenal insufficiency, which includes life-threatening conditions such as Addison’s disease, the CMA said.
The investigation found that the companies were able to inflate the price of hydrocortisone tablets by more than 10,000% compared with the original branded version on sale in 2008. This meant the amount the NHS had to pay for a single pack of 10mg tablets rose from 70p in April 2008 to £88 by March 2016.
The companies also paid would-be rivals to stay out of the market, the watchdog found.
“These are without doubt some of the most serious abuses we have uncovered in recent years,” said Andrea Coscelli, the chief executive of the CMA. “The actions of these firms cost the NHS – and therefore taxpayers – hundreds of millions of pounds.”
Before April 2008, the NHS spent about £500,000 a year on hydrocortisone tablets but this had risen to more than £80m by 2016.
The decision to increase the price of de-branded drugs meant that the NHS “had no choice but to pay huge sums of taxpayers’ money for life-saving medicines” and reduce the money available for patient care , Coscelli said.
“Our fine serves as a warning to any other drug firm planning to exploit the NHS.”
Accord-UK plans to appeal against the CMA’s decision. A spokesman said the company was “very disappointed” by the fine, which relates to activity before the company acquired Actavis in 2017. It said it has “done nothing but continuously reduce the price in the face of significant competition” since the acquisition.
“We maintain that the case a
저작권자 © 엠아이앤뉴스, 무단전재 및 재배포 금지